iMD Companies, Inc. (ICBU)
USD 0.0
(25.0%)
USD 0.0
(25.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 151.8 Thousand USD | 25.82% |
| 2022 | 120.65 Thousand USD | 35.58% |
| 2021 | 88.99 Thousand USD | 368.65% |
| 2020 | 18.99 Thousand USD | 19.95% |
| 2019 | 15.83 Thousand USD | -94.97% |
| 2018 | 314.98 Thousand USD | -95.26% |
| 2017 | 6.64 Million USD | 236.85% |
| 2016 | 1.97 Million USD | 570.4% |
| 2015 | 294.15 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 49.89 Thousand USD | -5.48% |
| 2024 Q1 | 52.78 Thousand USD | 10.96% |
| 2023 FY | 151.8 Thousand USD | 25.82% |
| 2023 Q3 | 21.27 Thousand USD | 16.54% |
| 2023 Q1 | 64.1 Thousand USD | 50.86% |
| 2023 Q2 | 18.25 Thousand USD | -71.52% |
| 2023 Q4 | 47.57 Thousand USD | 123.62% |
| 2022 Q2 | 88.88 Thousand USD | 149.6% |
| 2022 FY | 120.65 Thousand USD | 35.58% |
| 2022 Q3 | 16.32 Thousand USD | -81.63% |
| 2022 Q4 | 42.49 Thousand USD | 160.27% |
| 2022 Q1 | 35.61 Thousand USD | 361.93% |
| 2021 Q2 | 25.81 Thousand USD | 15.39% |
| 2021 Q4 | 7709.00 USD | -85.48% |
| 2021 Q3 | 53.1 Thousand USD | 105.75% |
| 2021 FY | 88.99 Thousand USD | 368.65% |
| 2021 Q1 | 22.37 Thousand USD | 0.0% |
| 2020 FY | 18.99 Thousand USD | 19.95% |
| 2019 FY | 15.83 Thousand USD | -94.97% |
| 2018 FY | 314.98 Thousand USD | -95.26% |
| 2017 FY | 6.64 Million USD | 236.85% |
| 2016 FY | 1.97 Million USD | 570.4% |
| 2015 FY | 294.15 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Bio Medica Corporation | 1.04 Million USD | 85.528% |
| Arrayit Corporation | 6.19 Million USD | 97.551% |
| Atlantic International Corp. | 5.57 Million USD | 97.279% |
| Biocept, Inc. | 29.4 Million USD | 99.484% |
| Bioqual, Inc. | 7.44 Million USD | 97.962% |
| CardioGenics Holdings Inc | 772.14 Thousand USD | 80.339% |
| DermTech, Inc. | 104.01 Million USD | 99.854% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 166.5 Million USD | 99.909% |
| HTG Molecular Diagnostics, Inc. | 22.62 Million USD | 99.329% |
| IDenta Corp. | 662.97 Thousand USD | 77.102% |
| Interpace Biosciences, Inc. | 20.23 Million USD | 99.25% |
| Integrative Health Technologies, Inc. | 38.88 Thousand USD | -290.445% |
| InVitro International | 661.32 Thousand USD | 77.045% |
| Lumos Diagnostics Holdings Limited | 7.09 Million USD | 97.861% |
| Many Bright Ideas Technologies Inc. | 58.11 Thousand USD | -161.235% |
| Medical Imaging Corp. | 1.91 Million USD | 92.061% |
| NovelStem International Corp. | 3.53 Million USD | 95.709% |
| Optigenex Inc. | 1.28 Million USD | 88.212% |
| PharmChem, Inc. | 2.93 Million USD | 94.821% |
| Proteome Sciences plc | 3.26 Million USD | 95.355% |
| Response Genetics, Inc | 25.31 Million USD | 99.4% |
| Rennova Health, Inc. | 7.67 Million USD | 98.023% |
| RushNet, Inc. | 1.78 Million USD | 91.516% |
| ScreenPro Security Inc. | 3.23 Million USD | 95.313% |
| Stella Diagnostics Inc. | 11.42 Million USD | 98.671% |
| StageZero Life Sciences Ltd. | 7.34 Million USD | 97.933% |
| Todos Medical Ltd. | 14.05 Million USD | 98.92% |